Filing Flows › Health Catalyst (HCAT) › R&D spending
Health Catalyst (HCAT) R&D spending by quarter
Health Catalyst's R&D spending was $11.0M in Q2 2026 (second quarter 2026), +13% from Q1 2026. Over the last 6 quarters it ranged from $9.8M (Q1 2026) to $15.2M (Q1 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $11.0M | +13% | -11% |
| Q1 2026 | $9.8M | -1% | -36% |
| Q4 2025 | $9.9M | -19% | — |
| Q3 2025 | $12.3M | -0.9% | — |
| Q2 2025 | $12.4M | -18% | — |
| Q1 2025 | $15.2M | — | — |
Q2 2026 at a glance
Health Catalyst, Q2 2026: revenue $70.5M (-13% year over year), operating margin -51.8%, net loss $40.5M, operating cash flow $275K. The chart follows the revenue to costs, profit and cash.
Questions
What is Health Catalyst's R&D spending?
Health Catalyst's R&D spending was $11.0M in Q2 2026 (second quarter 2026), +13% from Q1 2026.
How has Health Catalyst's R&D spending changed?
Over the last 6 quarters it ranged from $9.8M (Q1 2026) to $15.2M (Q1 2025).